Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2020-09-30 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for omitted pictures and no textual content or context to analyze. The true document length is only 171 characters, which is extremely short and contains no substantive information. There is no indication of any report, announcement, or filing type. Given the lack of content, the document cannot be classified as any specific report or announcement. According to the rules, such minimal content with no meaningful text defaults to Regulatory Filings (RNS) as a fallback category.
2020-09-30 English
Trading Window
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for omitted pictures and no substantive text or financial data. The true document length is only 113 characters, indicating it is extremely short and does not contain any report content. There is no indication of any report, announcement, or filing type. Given the lack of content, the document best fits the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2020-09-30 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed report of the results of a postal ballot and remote e-voting conducted by Neuland Laboratories Limited. It includes voting results, percentages, and a scrutinizer's report pursuant to Section 110 of the Companies Act, 2013, and related rules. The document is addressed to stock exchanges and includes official certifications by the company secretary and the scrutinizer. It does not contain financial statements or management discussion but focuses on the disclosure of voting results for shareholder resolutions. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is substantial and contains detailed voting data, confirming it is the actual voting results report, not just an announcement of report publication or a proxy solicitation.
2020-09-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges (BSE and NSE) regarding an analyst/institutional investor meeting held on September 9, 2020. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content describes the meeting participants and topics discussed, which were general business and information from earlier conference calls. The document does not contain any financial statements, detailed financial data, or comprehensive report content. It is essentially an announcement or intimation about the meeting rather than a full report or transcript. Given the short length (1580 characters) and the nature of the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-09-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges, referencing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides details about an analyst/institutional investor meeting held virtually on 07/09/2020. The content is an intimation or announcement about the meeting and discussions, not a full transcript or detailed report. The document length is only 1435 characters, indicating it is a brief announcement rather than a detailed report or transcript. There is no financial data or detailed analysis present. Therefore, this document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-09-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 60% confidence The document is extremely short (307 characters) and contains no substantive financial data or detailed content. It appears to be a brief tabular listing of a meeting date, an analyst or investor name, and a meeting type, with multiple images omitted. There is no indication of a full report, financial statements, or detailed disclosures. Given the brevity and format, this is likely a summary or announcement related to investor meetings rather than a full report or transcript. The best fitting category is Investor Presentation (IP), as it relates to meetings with analysts/investors, but since the content is minimal and no detailed presentation is included, it could also be considered a Regulatory Filing (RNS). However, given the presence of meeting details and analyst/investor references, Investor Presentation (IP) is the most appropriate classification with moderate confidence.
2020-08-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.